<DOC>
	<DOCNO>NCT01870388</DOCNO>
	<brief_summary>The main purpose study measure much study drug call baricitinib get blood stream long take body get rid . Healthy participant liver disease may enroll . The study last 7 day participant , include screening .</brief_summary>
	<brief_title>A Pharmacokinetic Study Baricitinib Participants With Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Inclusion Criteria ALL Participants : Male participant agree use 2 reliable method birth control female partner childbearing potential study least 3 month follow last dose study drug Women childbearing potential due surgical sterilization ( least 6 week surgical bilateral oophorectomy without hysterectomy least 6 week confirm tubal occlusion/tubal ligation ) confirm medical history , menopause Menopausal woman spontaneous amenorrhea least 12 month , induce medical condition medication folliclestimulating hormone ( FSH ) level great 40 milliinternational unit per milliliter ( mIU/mL ) ( unless participant take hormone replacement therapy [ HRT ] ) Have body mass index 18.5 40.0 kilogram per square meter ( kg/m^2 ) inclusive time screen Additional Inclusion Criteria Healthy Participants : Are overtly healthy participant , normal hepatic function stable chronic medical condition Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Additional Inclusion Criteria Hepatically Impaired Participants : Participants hepatic impairment classify ChildPugh score A B ( mild [ Group 3 , enrol ] moderate [ Group 2 ] impairment , respectively ) . Must diagnosis chronic hepatic impairment ( great 6 month ) , clinically significant change within 90 day prior study drug administration ( Day 1 ) . Participants may mild stable baseline medical condition neither condition treatment receive would negatively impact health participant study conduct Clinical laboratory test result deviation judge investigator compatible hepatic impairment participant , additional clinical significance study Exclusion Criteria ALL Participants : Have receive , within last 30 day , investigational product part clinical trial , concurrently enrol type medical research judge scientifically medically compatible study Persons previously complete withdrawn study investigate baricitinib , previously receive investigational product Women positive pregnancy test lactate Have current recent history ( le 30 day prior screen and/or less 45 day prior admission clinical research unit ) clinically significant bacterial , fungal , parasitic , viral ( exclude rhinopharyngitis ) , mycobacterial infection Have symptomatic herpes zoster herpes simplex infection within 90 day prior first dose Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Have expose live vaccine within 12 week prior first dose expect need/receive live vaccine ( include herpes zoster vaccination ) course study Additional Exclusion Criteria Healthy Participants : Show evidence acute chronic liver disease Show evidence hepatitis B and/or positive hepatitis B and/or positive hepatitis B surface antigen Show evidence hepatitis C and/or positive hepatitis C antibody Intend use overthecounter prescription medication and/or herbal supplement within 14 day prior dose study Additional Exclusion Criteria Liver Impaired Participants : Have creatinine clearance less equal 50 milliliter per minute ( mL/min ) use Cockcroft Gault formula Show evidence spontaneous bacterial peritonitis within 6 month dose Have variceal bleed within 3 month check Show evidence severe hyponatremia ( sodium le 120 millimolar per liter ( mmol/L ) Have severe encephalopathy ( Grade 3 4 ) Have moderate severe ascites ( moderately hepatically impaired participant ) Show presence portal shunt Have hemoglobin less 9.0 gram per deciliter ( g/dL ) Have serum bilirubin great 15 milligram per deciliter ( mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>